The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

Michelle J. Khan; Philip E. Castle; Attila T. Lörincz; Sholom Wacholder; Mark E. Sherman; David R. Scott; Brenda B. Rush; Andrew G. Glass; Mark Schiffman

doi:10.1093/jnci/dji187

July 19, 2005JNCI Journal of the National Cancer InstituteOpen Access

The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

View Full Paper

Ask AI

Bookmark

Share

Abstract

HPV screening that distinguishes HPV16 and HPV18 from other oncogenic HPV types may identify women at the greatest risk of > or = CIN3 and may permit less aggressive management of other women with oncogenic HPV infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khan et al. (2005) studied this question.

synapsesocial.com/papers/69dcb9bba5c75be4cfe53a3f https://doi.org/10.1093/jnci/dji187

View Full Paper

Ask AI

Bookmark

Share

The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

Abstract

Discussion

Cite This Study

The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JNCI Journal of the National Cancer Institute

Keep reading

More related papers

More from JNCI Journal of the National Cancer Institute